Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Overview of attention for article published in Clinical Cancer Research, June 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 71 tweets from 60 users, with an upper bound of 218,204 followers.

正しいリンクはこっち。 https://t.co/rSw8NtIy13 あとでゆっくり読む。

RT @OncoViews: Latest PALOMA-3 trial results have shown improved OS in people with HR+/HER2 #BreastCancer treated with palbociclib plus ful…

RT @OncoViews: Latest PALOMA-3 trial results have shown improved OS in people with HR+/HER2 #BreastCancer treated with palbociclib plus ful…

RT @OncoViews: Latest PALOMA-3 trial results have shown improved OS in people with HR+/HER2 #BreastCancer treated with palbociclib plus ful…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 67 additional tweets.